Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia

Stefan Peinert, Constantine S. Tam, H. Miles Prince, John Scarlett, Max M. Wolf, E. Henry Januszewicz, David Westerman, John F. Seymour

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

Treatment with single-agent chemotherapy or rituximab (R) is safe and moderately effective for patients with Waldenström macroglobulinemia (WM). We analyzed the efficacy and toxicity of fludarabine (F)-combinations. Twenty-nine treatment episodes were administered to 27 patients, including FC (F 25mg/m2 days 1-3, cyclophosphamide C 250mg/m2 days 1-3; n = 7), FCR (FC +R 375mg/m2 day 1; n = 18), FM (F + mitoxantrone M 10mg/m2 day 1; n = 3), and FR (n = 1). Patient characteristics were median age 57 years (36-89), 83% male, 10 previously untreated (34%). In total, 123 cycles were administered, a median of four (2-6) per patient. Grade ≥ 3 neutropenia and infections complicated 28% and 3% of cycles, respectively. Responses were achieved in 26 cases (90%), one complete, 23 partial, and two minor. The median progression-free survival was 43.1 months, and at a median follow-up of 66.5 months the actuarial 5- and 10-year overall survival-rates were 88% and 75%, respectively. All 10 previously untreated patients responded (one CR, nine PR), and were alive at a median follow-up of 50 (6-106) months. Three heavily pretreated patients subsequently developed AML/MDS (one fatal) at 56, 61, and 91 months post F-based treatment. F-combination therapy is highly active in WM, both untreated and alkylator-refractory. However, a possible contribution to the cumulative risk of treatment-related MDS/AML requires ongoing monitoring.

Original languageEnglish
Pages (from-to)2188-2197
Number of pages10
JournalLeukemia and Lymphoma
Volume51
Issue number12
DOIs
Publication statusPublished - Dec 2010
Externally publishedYes

Keywords

  • fludarabine
  • nucleoside analog
  • outcome
  • treatment
  • Waldenstrm macroglobulinemia

Cite this